Showing results (1-10 of 121) with videos related to
Sort By:
Pageof 13
Current Rheumatology Reports|March 27, 2013
Infectious complications in juvenile idiopathic arthritisAndrew Hurd, Timothy BeukelmanF1000Prime Reports|April 26, 2014
Treatment advances in systemic juvenile idiopathic arthritisTimothy BeukelmanPediatric Rheumatology Online Journal|August 18, 2010
Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?Randy Q Cron, Timothy BeukelmanCurrent Rheumatology Reports|February 5, 2013
What is the background incidence of malignancy in children with rheumatic disease?Melissa L Mannion, Timothy BeukelmanPediatric Clinics of North America|July 23, 2018
Juvenile Idiopathic Arthritis: Oligoarthritis and PolyarthritisCourtney B Crayne, Timothy BeukelmanCurrent Opinion in Rheumatology|July 11, 2014
Risk of malignancy associated with biologic agents in pediatric rheumatic diseaseMelissa L Mannion, Timothy BeukelmanRheumatic Diseases Clinics of North America|October 12, 2021
Pharmacosurveillance in Juvenile Idiopathic ArthritisNatalie J Shiff, Timothy BeukelmanJournal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|February 19, 2019
Primary Oral Presentation of Sarcoidosis in a Pediatric PatientChad Dammling, Peter Waite, Timothy BeukelmanJournal of Scleroderma and Related Disorders|April 6, 2022
Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan FoeldvariJournal of Scleroderma and Related Disorders|April 6, 2022
The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United StatesTimothy Beukelman, Fenglong Xie, Ivan FoeldvariPageof 13